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purpose: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Everolimus-eluting stent (EES) and 
SeQuent™ Please, a drug-eluting balloon (DEB) on the outcome of patients with diffuse in-stent restenosis (D-ISR) after bare metal stent (BMS) 
implantation. 
methods: A prospective analysis of 1078 patients with 1251 D-ISR lesions (427 SES, 363 PES, 232 EES and 229 DEB) in six high volume Asian 
centers after successful stent implantation (SES: LAD 45.7%, LCX 27.9%, RCA 26.4%) (PES: LAD 46.0%, LCX 22.9%, RCA 31.1%) (EES: LAD 50.0%, 
LCX 21.0%, RCA 29.0%) (DEB: LAD 54.0%, LCX 23.0%, RCA 23.0%) was performed. The study endpoints were major adverse cardiac events (MACE) 
and target lesion revascularization (TLR) at 12 and 24 months. 
results: See table for clinical Results.
conclusion: (1) The use of SES, PES, EES and DEB in patients with D-ISR seems to be favorable in terms of in-hospital clinical outcome. (2) 
Patients treated with DEB showed higher restenosis rate and TLR compared with DES. 
SES PES EES DEB
Number of patients/lesions 365/427 313/363 200/232 200/229
Procedural success (%) 100 100 100 98.0
MACE at 30 days (%) 0.9 1.0 0 2.0
Proximal RD (mm) 2.86±0.74 2.80±0.80 2.79±0.71 2.81±0.79
MLD post procedure (mm) 2.60±0.77 2.61±0.74 2.66±0.76 2.28±0.78
MLD at 12 months (mm) 2.33±0.79 2.19±0.75 2.44±0.71 1.89±0.89
MLD at 24 months (mm) 2.19±0.84 2.06±0.80 2.31±0.75 1.66±0.90
TLR at 12 months (%) 6.9 11.5 5.0 27.5*
MACE at 12 months (%) 7.8 12.5 5.0 29.0*
TLR at 24 months (%) 8.2 13.1 7.5 32.0*
MACE at 24 months (%) 10.4 16.3 9.0 34.0*
RD: reference diameter, MLD: minimum lumen diameter, *p<0.05 vs SES, PES and EES.
